“Lebrikizumab vs Other Systemic Monotherapies for Moderate to Severe Atopic Dermatitis: Network Meta-analysis of Short-term Efficacy”, J of Skin, vol. 9, no. 1, p. s517, Jan. 2025, doi: 10.25251/skin.9.supp.517.